Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Net Income towards Common Stockholders: 2021-2025

Historic Net Income towards Common Stockholders for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to -$1.7 million.

  • InMed Pharmaceuticals' Net Income towards Common Stockholders fell 2.92% to -$1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.2 million, marking a year-over-year decrease of 20.58%. This contributed to the annual value of -$8.2 million for FY2025, which is 6.34% down from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Net Income towards Common Stockholders of -$1.7 million as of Q3 2025, which was up 3.43% from -$1.8 million recorded in Q2 2025.
  • InMed Pharmaceuticals' 5-year Net Income towards Common Stockholders high stood at -$336,591 for Q2 2023, and its period low was -$7.9 million during Q2 2022.
  • Over the past 3 years, InMed Pharmaceuticals' median Net Income towards Common Stockholders value was -$1.8 million (recorded in 2025), while the average stood at -$1.8 million.
  • In the last 5 years, InMed Pharmaceuticals' Net Income towards Common Stockholders soared by 95.72% in 2023 and then crashed by 473.57% in 2024.
  • InMed Pharmaceuticals' Net Income towards Common Stockholders (Quarterly) stood at -$4.3 million in 2021, then surged by 51.01% to -$2.1 million in 2022, then climbed by 29.55% to -$1.5 million in 2023, then tumbled by 74.20% to -$2.6 million in 2024, then decreased by 2.92% to -$1.7 million in 2025.
  • Its Net Income towards Common Stockholders was -$1.7 million in Q3 2025, compared to -$1.8 million in Q2 2025 and -$2.1 million in Q1 2025.